A double-blind, placebo-controlled evaluation of dose related safety and efficacy of epicutaneously applied IDEA-033 [ketoprofen] for 3 months treatment of OA [osteoarthritis] of the knee followed by a double-blind, dose-controlled evaluation of safety and efficacy of epicutaneously applied IDEA-033 for 12 weeks treatment of OA of the knee

Trial Profile

A double-blind, placebo-controlled evaluation of dose related safety and efficacy of epicutaneously applied IDEA-033 [ketoprofen] for 3 months treatment of OA [osteoarthritis] of the knee followed by a double-blind, dose-controlled evaluation of safety and efficacy of epicutaneously applied IDEA-033 for 12 weeks treatment of OA of the knee

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Ketoprofen (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 17 Nov 2008 Results were presented at EULAR 2008. Actual patient numbers added. Link to ADNM 801116646 added.
    • 14 Jun 2007 Results data presented at EULAR 2007 (1078891).
    • 23 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top